@media (max-width: 768px) {
                .image-container {
                    width: 100% !important;
                    float: none !important;
                    margin: 0 0 1rem 0 !important;
                }
            }
        



Image source: The Mo

Caris Life (CAI) Q3 2026 Earnings Call Transcript

(RTTNews) - Caris Life Sciences, Inc. (CAI), a TechBio company focused on precision medicine and molecular profiling, reported lower third-quarter 2026 net income as operating expenses increased, despite strong revenue growth. The company raised its full-year revenue guidance fol

Caris Q3 Net Income Declines 37% Despite 27% Revenue Growth; Raises FY26 Outlook 

(RTTNews) - Caris Life Sciences, Inc. (CAI) reported a decline in third-quarter net income as expenses increased. The TechBio company posted 27% revenue growth for the quarter and raised its full-year revenue guidance.

Caris Q3 Profit Falls On Higher Expenses; Raises FY26 Revenue Guidance After 27% Revenue Growth 

Insider reported a trade at Caris Life Sciences, Inc.

Caris Life Sciences, Inc. filed a 144

Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  Bristol Myers Squibb (BMY) This Year?

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Caris Life Sciences, Inc. News